Clinical Insights: June 2020 | Oncology Nursing News
CE lesson worth 1 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.
Related Articles
Zanubrutinib May Affect the Heart Less Than Ibrutinib and Acalabrutinib in CLL/SLL
Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.
FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC
Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.
Rx Road Map: Abemaciclib (Verzenio)
Sarah Montini, BSN, RN, OCN, provides an in-depth look at abemaciclib for the treatment of patients with breast cancer in a downloadable reference sheet.
Lumisight and Lumicell DVS Receive FDA Approval to Detect Residual Breast Cancer
The optical imaging agent Lumisight and the Lumicell Direct Visualization System received approval from the FDA for fluorescence imaging in breast cancer.
Recognition of the Advanced Practice Preceptor Role in Oncology
A tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.
Tamibarotene-Based Combo Receives Fast Track Designation from the FDA for AML
The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.
Survival Benefit Persists at 3 Years With Durvalumab Plus Chemo in Advanced Biliary Tract Cancer
Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.
Preoperative Systemic Therapy May Improve Survival vs Mastectomy in HER2+ Breast Cancer
Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.
Opinion: Osimertinib Plus Chemo May Enhance Outcomes in Metastatic EGFR-Mutated Lung Cancer
Oncology nurses play a vital role in informing patients about the importance of molecular testing and brain imaging in EGFR-mutated lung cancer.
FDA’s ODAC Supports MRD as an End Point for Approval in Multiple Myeloma
The FDA’s Oncologic Drugs Advisory Committee voted in favor of minimal residual disease as an end point to support accelerated approval of multiple myeloma treatments.